1. Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity.
- Author
-
Moustafa AH, AboulMagd AM, Ali AM, Khodairy A, Marzouk AA, Nafady A, and T M Nemr M
- Subjects
- Humans, Apoptosis drug effects, Guanidine pharmacology, Guanidine chemistry, Guanidine chemical synthesis, Guanidine analogs & derivatives, HL-60 Cells, Leukemia drug therapy, Leukemia pathology, Molecular Docking Simulation, Molecular Structure, Structure-Activity Relationship, Cyanamide chemical synthesis, Cyanamide chemistry, Cyanamide pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Design, Drug Screening Assays, Antitumor, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors chemical synthesis, Protein Kinase Inhibitors chemistry, Proto-Oncogene Proteins c-abl antagonists & inhibitors, Proto-Oncogene Proteins c-abl metabolism, src-Family Kinases antagonists & inhibitors, src-Family Kinases metabolism
- Abstract
A new series of benzene-sulfonamide derivatives 3a-i was designed and synthesized via the reaction of N-(pyrimidin-2-yl)cyanamides 1a-i with sulfamethazine sodium salt 2 as dual Src/Abl inhibitors. Spectral data IR,
1 H-,13 C- NMR and elemental analyses were used to confirm the structures of all the newly synthesized compounds 3a-i and 4a-i. Crucially, we screened all the synthesized compounds 3a-i against NCI 60 cancer cell lines. Among all, compound 3b was the most potent, with IC50 of 0.018 μM for normoxia, and 0.001 μM for hypoxia, compared to staurosporine against HL-60 leukemia cell line. To verify the selectivity of this derivative, it was assessed against a panel of tyrosine kinase EGFR, VEGFR-2, B-raf, ERK, CK1, p38-MAPK, Src and Abl enzymes. Results revealed that compound 3b can effectively and selectively inhibit Src/Abl with IC50 0.25 μM and Abl inhibitory activity with IC50 0.08 μM, respectively, and was found to be more potent on these enzymes than other kinases that showed the following results: EGFR IC50 0.31 μM, VEGFR-2 IC50 0.68 μM, B-raf IC50 0.33 μM, ERK IC50 1.41 μM, CK1 IC50 0.29 μM and p38-MAPK IC50 0.38 μM. Moreover, cell cycle analysis and apoptosis performed to compound 3b against HL-60 suggesting its antiproliferative activity through Src/Abl inhibition. Finally, molecular docking studies and physicochemical properties prediction for compounds 3b, 3c, and 3 h were carried out to investigate their biological activities and clarify their bioavailability., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF